Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Speciality MedicinesBOM:544738 -6.76%21 EBITDA Margin % is 20.21% as of Mar. 2026, which is 26% above its 10-year median of 16.06. GuruFocus rates BOM:544738 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Speciality Medicines ranks better than 68.82% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Speciality Medicines EBITDA Margin % Related Terms
Speciality Medicines EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Speciality Medicines's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Speciality Medicines EBITDA Margin % Chart
Speciality Medicines Annual Data
Trend
Mar22
Mar23
Mar24
Mar25
Mar26
EBITDA Margin %
5.62
15.54
19.59
16.06
19.27
Speciality Medicines Semi-Annual Data
Mar22
Mar23
Mar24
Mar25
Mar26
EBITDA Margin %
0.00
0.00
0.00
14.57
20.21
BOM:544738 vs ZTS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Speciality Medicines's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Speciality Medicines EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Speciality Medicines's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Speciality Medicines's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Speciality Medicines (BOM:544738) has a EBITDA Margin % of 20.21% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Speciality Medicines and its competitors. This is 26% above median its historical median of 16.06. Over the past decade, Speciality Medicines' EBITDA Margin % has ranged from 5.62 to 20.21. According to the industry distribution chart, Speciality Medicines ranks #299 out of 959 companies in the Drug Manufacturers industry, placing it in the top 31.2%.
Is Speciality Medicines' EBITDA Margin % too high?
Speciality Medicines' current EBITDA Margin % of 20.21% is 26% above median its 10-year median of 16.06. Over the past 10 years, this metric has ranged from a low of 5.62 to a high of 20.21. The Drug Manufacturers industry median EBITDA Margin % is 12.11. Speciality Medicines' value of 20.21% is 66.9% above this industry median. Based on the distribution chart, Speciality Medicines ranks #299 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Speciality Medicines has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Speciality Medicines' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Speciality Medicines ranks #299 out of 959 companies for EBITDA Margin %. This puts Speciality Medicines in the upper half of its industry. The industry median EBITDA Margin % is 12.11. Speciality Medicines' value of 20.21% is 66.9% above this benchmark. Historically, Speciality Medicines' own EBITDA Margin % has ranged from 5.62 to 20.21 over the past decade. While the company's 10-year median is 16.06 vs. the industry median of 12.11, Speciality Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.11, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Speciality Medicines's current EBITDA Margin % of 20.21% is 66.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Speciality Medicines and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Speciality Medicines's current EBITDA Margin % is 20.21%, which is 26% above median its own 10-year median of 16.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Speciality Medicines stock overvalued right now?
Speciality Medicines (BOM:544738) has a current EBITDA Margin % of 20.21%. The current EBITDA Margin % is 20.21%, which is 26% above median its 10-year median of 16.06 and 66.9% above the Drug Manufacturers industry median of 12.11. Speciality Medicines' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Speciality Medicines (BOM:544738), the current EBITDA Margin % is 20.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Speciality Medicines Ltd is engaged in the marketing and distribution of finished formulations of specialty pharmaceutical products, comprising oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases. Its product range includes various dosage forms such as tablets, capsules, syrups, injections, infusions, inhalers, sprays, and topical formulations. The company operates through two business models: (a) Manufacturing, through contract manufacturing basis, and (b) Marketing and distribution of specialty pharmaceutical products sourced from manufacturers. The majority of the company's revenue is derived from the sale of its projects, mainly through exports to other countries.
21GF Score
Get the complete analysis for BOM:544738
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544738 has been successfully added to your 
